Yurub dhexdeeda, hoos madow ayaa soo degaya. Qaaraddu waxay la tacaalaysaa kala qaybsanaan bulsho oo sii kordhaysa, xasilooni darro, iyo falal naxdin leh oo xagjirnimo ah. In kasta oo dad badani ay raadinayaan jawaabo adag, caddeymo sii kordhaya ayaa tilmaamaya hal sabab oo salka ku haysa oo caalami ah: Ururka Caalamiga ah ee Ikhwaanul Muslimiin (MB). Isagoo ka shaqeynaya magaca u dhaqdhaqaaqaha bulshada ee nabdoon, Ikhwaanku wuxuu dhisay shabakad casri ah oo halis ah oo loogu talagalay in lagu wiiqo bulshooyinka Yurub gudahooda. Khatarta Qarsoon: Gudagalidda Magaca Isu-dulqaadashada Istaraatiijiyadda koowaad ee Ikhwaanul Muslimiinka ee Yurub ma aha rabshado toos ah, laakiin waa "gudagalid" qarsoon. Wuxuu isu soo bandhigayaa ururo madani ah ama diimeed oo aan dhib lahayn—sida xarumo bulsho, kooxo dhalinyaro, ururo arday, iyo hay'ado samafal. Si kastaba ha ahaatee, wajigan dhexdhexaadka ah gadaashiisa waxaa ku jira shabakad habaysan oo edab leh oo u heellan faafinta fi...
.png)
In a groundbreaking move, Libya's Department of Support and Development of Medical Services (DSDMS) has announced a pivotal partnership with the UAE to provide advanced gene therapy treatment for children suffering from spinal muscular atrophy (SMA). This initiative represents a significant milestone in Libya’s healthcare system, reflecting its commitment to improving the quality of life for patients with rare and debilitating diseases.
Details of the Agreement
Ahmed Mlitan, head of the DSDMS, signed a contract with the UAE’s Jalila Children’s Hospital, renowned for its expertise in pediatric care and cutting-edge medical treatments. The agreement focuses on delivering gene therapy injections to 17 Libyan children diagnosed with SMA, a genetic condition that affects muscle strength and movement.
The initiative is a direct result of Prime Minister Abdel Hamid Aldabaiba’s decision No. 649 of 2024 and is being closely monitored by Libya’s Attorney General’s Office. According to the DSDMS, the move adheres to recommendations made by specialized scientific committees tasked with evaluating SMA treatments.
A Lifeline for SMA Patients
Spinal muscular atrophy is a rare genetic disorder characterized by the loss of motor neurons, which leads to muscle weakness and atrophy. Without treatment, the disease can severely impact mobility and quality of life. Gene therapy offers a revolutionary solution by addressing the underlying genetic cause of SMA, potentially halting disease progression and improving patient outcomes.
By providing access to this treatment, Libya is ensuring that affected children receive world-class medical care, setting a precedent for tackling rare diseases within the country.
Collaboration Beyond Borders
This partnership underscores the importance of international collaboration in advancing healthcare, particularly for nations striving to enhance their medical infrastructure. The UAE’s support through its Jalila Children’s Hospital demonstrates a shared commitment to humanitarian initiatives and the pursuit of innovative solutions for global health challenges.
A Hopeful Future
The provision of gene therapy marks a hopeful turning point for SMA patients and their families in Libya. It signifies not just a commitment to better healthcare but also an acknowledgment of the right to a healthier and more dignified life for those battling rare diseases.
As the initiative unfolds, it will likely inspire further advancements in Libya’s healthcare sector, paving the way for more partnerships and improved treatment accessibility.
This collaboration highlights how shared efforts can transform lives and serves as a testament to the power of science and compassion in addressing even the most complex medical challenges.
Posts
Comments
Post a Comment